Abstract:Background: The nuclear receptor REV-ERB alpha (nuclear receptor subfamily 1, Group D member 1, NR1D1) is one of the essential components of the circadian clock which modulates cell proliferation, glucose metabolism, inflammation, and many other biological processes. Modulation of these processes are also relevant to cancer development. Previous studies have suggested that activation of REV-ERBa correlates with cancer cell senescence and death, but how REV-ERBa play roles in tumor progression require further elucidation. Methods: We investigated the expression of REV-ERB alpha in clinical samples by immunohistochemistry (IHC). REV-ERB alpha is downregulated by shorth hairpin RNA (shRNA). The gene expression level of each group was detected by Western blot analysis. The effects of REV-ERB alpha downregulation on apoptosis and cell cycles was assessed by flow cytometry assay. A549 cell growth curve under different treatments measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Cell invasion ability under different treatments was measured by Transwell assay. Immunostaining analysis was also used for evaluating the effects of downregulation of REV-ERB alpha on nuclear factor-kappa B (NF-kappa B). Results: Compared to 81.8% (54/66) of samples exhibiting a lower expression level of REV- ERB alpha in cancer tissue than in paired normal tissue, only 18.2% (12/66) were higher or equally expressed in lung cancer tissue. Furthermore, downregulation of REV-ERB alpha by RNA interference can significantly enhance the transcription of nuclear factor-kappa B (NF-kappa B), while the expression of p53 remained the same. Downregulation of REV-ERBa was also shown to stimulate the invasion and promote the proliferation of lung adenocarcinoma cell line A549. Conclusions: Our findings suggest that tumorigenesis and progression of lung carcinoma is relevant to downregulation or inhibition of REV-ERB alpha. This pathophysiological process also correlates with regulation of the NF-kappa B signaling pathway, indicating that REV-ERB alpha is a potential target of lung cancer therapy.

Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming

Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence

Retinoic acid-related orphan receptor RORβ, circadian rhythm abnormalities and tumorigenesis (Review)

Retinoic Acid-Related Orphan Receptor Ror Beta, Circadian Rhythm Abnormalities And Tumorigenesis

Functional Characterization of Circadian Nuclear Receptors REV-ERBα and REV-ERBβ in Human Osteosarcoma Cell Cultures

Rev-erbα inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells

REV-ERBα Reduction is Associated with Clinicopathological Features and Prognosis in Human Gastric Cancer.

Downregulation of REV-ERBα is Associated with the Progression of Lung Adenocarcinoma.

TM-06 * MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS

Endogenous retroviruses mediate transcriptional rewiring in response to oncogenic signaling in colorectal cancer

CREB1 Contributes Colorectal Cancer Cell Plasticity by Regulating Lncrna CCAT1 and NF-κB Pathways

Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis

Circadian clock protein Rev-erbα regulates neuroinflammation

Ikk Beta Enforces A Lin28b/Tcf7l2 Positive Feedback Loop That Promotes Cancer Cell Stemness And Metastasis

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells

An Intrinsically Disordered Region Controlling Condensation of a Circadian Clock Component and Rhythmic Transcription in the Liver.

Redundant Function of REV-ERBα and Β and Non-essential Role for BMAL1 Cycling in Transcriptional Regulation of Intracellular Circadian Rhythms

Data from IKKβ Enforces a LIN28B/TCF7L2 Positive Feedback Loop That Promotes Cancer Cell Stemness and Metastasis

SR9009 Induces a REV-ERB Dependent Anti-Small-cell Lung Cancer Effect Through Inhibition of Autophagy.

Control of Cellular Differentiation Trajectories for Cancer Reversion